Chronic treatment with the peroxisome proliferator-activated receptor α agonist Wy-14,643 attenuates myocardial respiratory capacity and contractile function

By Zungu Makhosazane   Young Martin   Stanley William   Essop M.  

Molecular and Cellular Biochemistry, Vol. 330, Iss. 1-2, 2009-10 ,pp. : 55-62

Springer Publishing Company

Access to resources Recommend Favorite

Expression of Peroxisome Proliferator-Activated Receptor  (PPAR) in Primary Cultures of Human Vascular Endothelial Cells

By Inoue I.   Shino K.   Noji S.   Awata T.   Katayama S.  

Biochemical and Biophysical Research Communications, Vol. 246, Iss. 2, 1998-05 ,pp. : 370-374

Elsevier

Access to resources Recommend Favorite

Stabilization of Peroxisome Proliferator-Activated Receptor α by the Ligand

By Hirotani M.   Tsukamoto T.   Bourdeaux J.   Sadano H.   Osumi T.  

Biochemical and Biophysical Research Communications, Vol. 288, Iss. 1, 2001-10 ,pp. : 106-110

Elsevier

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor α (PPARα) Activators, Bezafibrate and Wy-14,643, Increase Uncoupling Protein-3 mRNA Levels without Modifying the Mitochondrial Membrane Potential in Primary Culture of Rat Preadipocytes

By   Alegret M.   Sánchez R.   Adzet T.   Laguna J.C.   Vázquez M.  

Archives of Biochemistry and Biophysics, Vol. 380, Iss. 2, 2000-08 ,pp. : 353-359

Elsevier

Access to resources Recommend Favorite

Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by Pioglitazone

By Sakamoto J.   Kimura H.   Moriyama S.   Odaka H.   Momose Y.   Sugiyama Y.   Sawada H.  

Biochemical and Biophysical Research Communications, Vol. 278, Iss. 3, 2000-11 ,pp. : 704-711

Elsevier

Access to resources Recommend Favorite